Skip to main content

Bluebird Bio, Inc. (BLUE)

NASDAQ: BLUE · Delayed Price · USD
18.64
-0.02 (-0.11%)
Pre-market:Sep 24, 2021 5:49 AM EDT
18.66
0.66 (3.67%)
At close: Sep 23, 4:00 PM
Market Cap1.26B
Revenue (ttm)50.25M
Net Income (ttm)-842.13M
Shares Out67.58M
EPS (ttm)-12.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume665,740
Open18.20
Previous Close18.00
Day's Range17.96 - 18.71
52-Week Range17.14 - 59.32
Beta1.60
AnalystsBuy
Price Target24.13 (+29.3%)
Est. Earnings DateNov 4, 2021

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (C...

IndustryBiotechnology
IPO DateJun 19, 2013
Employees1,201
Stock ExchangeNASDAQ
Ticker SymbolBLUE
Full Company Profile

Financial Performance

In 2020, Bluebird Bio's revenue was $250.73 million, an increase of 461.25% compared to the previous year's $44.67 million. Losses were -$618.70 million, -21.65% less than in 2019.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for Bluebird Bio stock is "Buy." The 12-month stock price forecast is 24.13, which is an increase of 29.31% from the latest price.

Price Target
$24.13
(29.31% upside)
Analyst Consensus: Buy

News

bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia

bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.

1 day ago - Zacks Investment Research

Bluebird Bio Files US Application For β-thalassemia Gene Therapy

Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy. The application covers adu...

1 day ago - Benzinga

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Dru...

2 days ago - Business Wire

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...

1 week ago - InvestorPlace

2seventy bio Announces Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its...

1 week ago - Business Wire

Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

7 Busted Biotech Stocks Due for a Rebound

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...

Other symbols:AMRNARCTARNASAVATBPH
2 weeks ago - InvestorPlace

bluebird bio Secures $75 Million in Private Placement Equity Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalent...

2 weeks ago - Business Wire

bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced key management and board appointments in advance of the company's planned separation, targeted for mid-October, 2021....

2 weeks ago - Business Wire

3 Beaten-Down Biotech Stocks to Buy Right Now

These biotech stocks might be down, but they're not out.

Other symbols:LHDXVRTX
1 month ago - The Motley Fool

bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.

1 month ago - Zacks Investment Research

SVB Leerink Says 'We Were Wrong,' Slashes Bluebird Bio Price Target

After the FDA placed a clinical hold on Bluebird Bio Inc's (NASDAQ:BLUE) cerebral adrenoleukodystrophy gene therapy, SVB Leerink downgraded the stock to Market Perform from Outperform. Analyst Mani Foro...

1 month ago - Benzinga

Why Bluebird Bio Stock Is Crashing Today

The drugmaker had a double whammy of bad news.

1 month ago - The Motley Fool

Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of -9.82% and -55.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: bluebird bio Q2 Earnings

Shares of bluebird bio (NASDAQ:BLUE) moved higher by 0.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 852.78% year over year to ($3.43), w...

1 month ago - Benzinga

bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2021 and provided operational updates,...

1 month ago - Business Wire

bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 a...

1 month ago - Business Wire

bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to pu...

1 month ago - Business Wire

Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.

Other symbols:CRSPVRTX
1 month ago - The Motley Fool

Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

SAN DIEGO & BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early r...

1 month ago - Business Wire

bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Tha...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel,...

2 months ago - Business Wire

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

Neither healthcare stock has performed well so far this year.

Other symbols:MRKOGN
2 months ago - The Motley Fool

Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC

European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE) Zynteglo (betibeglogene autotemcel gene ther...

2 months ago - Benzinga

BLUE Brings Back Treatment From Marketing Suspension

The shares of bluebird bio Inc (NASDAQ:BLUE) are higher today, on news that the biotech company is lifting its voluntary marketing suspension of its gene therapy treatment, Zynteglo.

2 months ago - Schaeffers Research